Design, Synthesis, and Structure–Activity Relationship of Tetrahydropyrido[4,3-<i>d</i>]pyrimidine Derivatives as Potent Smoothened Antagonists with <i>in Vivo</i> Activity
作者:Wenfeng Lu、Yongqiang Liu、Haikuo Ma、Jiyue Zheng、Sheng Tian、Zhijian Sun、Lusong Luo、Jiajun Li、Hongjian Zhang、Zeng-Jie Yang、Xiaohu Zhang
DOI:10.1021/acschemneuro.7b00153
日期:2017.9.20
often arises among tumor cells during treatment with vismodegib. There is clearly an urgent need to explore novel Smo antagonists with improved potency and efficacy. Through a scaffold hopping strategy, we have identified a series of novel tetrahydropyrido[4,3-d]pyrimidine derivatives, which exhibited effective inhibition of Hh signaling. Among them, compound 24 is three times more potent than vismodegib
髓母细胞瘤是儿童中最普遍的脑肿瘤之一。异常的刺猬(Hh)通路信号被认为与髓母细胞瘤的发生和发展有关。Vismodegib是第一种基于FDA批准的基于抑制异常刺猬信号转导的癌症疗法,其靶点是平滑化(Smo),这是Hh通路的核心G蛋白偶联受体(GPCR)。尽管vismodegib在肿瘤治疗中显示出有希望的治疗效果,但高剂量下的非线性药代动力学(PK)曲线引起了人们的关注,部分原因是水溶性低。许多患者经历不良事件,例如肌肉痉挛和体重减轻。另外,在用vismodegib治疗期间,肿瘤细胞之间经常产生耐药性。显然迫切需要探索具有增强的效力和功效的新型Smo拮抗剂。通过脚手架跳跃策略,我们确定了一系列新型的四氢吡啶并[4,3-d ]嘧啶衍生物,其显示出对Hh信号传导的有效抑制。其中,在NIH3T3-GRE-Luc报告基因检测中,化合物24的效力是vismodegib的三倍。与vismodegib相比,